{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:36Z","timestamp":1792782996173,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T00:00:00Z","timestamp":1579478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1KL2TR002554"],"award-info":[{"award-number":["1KL2TR002554"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA241390"],"award-info":[{"award-number":["1K08CA241390"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08CA228631"],"award-info":[{"award-number":["K08CA228631"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI064518"],"award-info":[{"award-number":["P30AI064518"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA014236"],"award-info":[{"award-number":["P30CA014236"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000124","name":"Office of Research on Women's Health","doi-asserted-by":"publisher","award":["K12HD043446"],"award-info":[{"award-number":["K12HD043446"]}],"id":[{"id":"10.13039\/100000124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0297"],"award-info":[{"award-number":["W81XWH-17-1-0297"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IBC Network Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10549-020-05529-1","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T02:02:28Z","timestamp":1579485748000},"page":"207-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients"],"prefix":"10.1007","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0876-975X","authenticated-orcid":false,"given":"Oluwadamilola M.","family":"Fayanju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Greenup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Plichta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Rosenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Force","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri R.","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faina","family":"Nakhlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Shelley","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,20]]},"reference":[{"issue":"13","key":"5529_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jnci\/dji172","volume":"97","author":"KW Hance","year":"2005","unstructured":"Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966\u2013975","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"5529_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2014.09.003","volume":"93","author":"DJP van Uden","year":"2015","unstructured":"van Uden DJP, van Laarhoven HWM, Westenberg AH, de Wilt JHW, Blanken-Peeters CFJM (2015) Inflammatory breast cancer: an overview. Crit Rev Oncol\/Hematol. 93(2):116\u2013126","journal-title":"Crit Rev Oncol\/Hematol."},{"key":"5529_CR3","unstructured":"\"Inflammatory Breast Cancer.\" NCCN Guideline Version 2.2019. https:\/\/www.nccn.org\/. Accessed 2019 July 01."},{"issue":"6","key":"5529_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im Y-H et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791\u2013800","journal-title":"Lancet Oncol"},{"issue":"3","key":"5529_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10549-016-3889-6","volume":"158","author":"ZA Nahleh","year":"2016","unstructured":"Nahleh ZA, Barlow WE, Hayes DF et al (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158(3):485\u2013495","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"5529_CR6","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1245\/s10434-017-5903-6","volume":"24","author":"F Nakhlis","year":"2017","unstructured":"Nakhlis F, Regan MM, Warren LE et al (2017) The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol 24(9):2563\u20132569","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"5529_CR7","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.7150\/jca.31176","volume":"10","author":"GR Devi","year":"2019","unstructured":"Devi GR, Hough H, Barrett N et al (2019) Perspectives on inflammatory breast cancer (IBC) research, clinical management and community engagement from the Duke IBC consortium. J Cancer. 10(15):3344\u20133351","journal-title":"J Cancer."},{"issue":"5","key":"5529_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","volume":"27","author":"JM Classe","year":"2009","unstructured":"Classe JM, Bordes V, Campion L et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol: Off J Am Soc Clin Oncol 27(5):726\u2013732","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"5529_CR9","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol: Off J Am Soc Clin Oncol 23(12):2694\u20132702","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"5529_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ejca.2015.03.014","volume":"51","author":"M van der Heiden-van der Loo","year":"2015","unstructured":"van der Heiden-van der Loo M, de Munck L, Sonke GS et al (2015) Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: identification rate and influence on axillary treatment. Eur J Cancer. 51(8):915\u2013921","journal-title":"Eur J Cancer."},{"issue":"3","key":"5529_CR11","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol: Off J Am Soc Clin Oncol. 33(3):258\u2013264","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol."},{"issue":"14","key":"5529_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (alliance) clinical trial. JAMA 310(14):1455\u20131461","journal-title":"JAMA"},{"issue":"7","key":"5529_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609\u2013618","journal-title":"Lancet Oncol"},{"issue":"10","key":"5529_CR14","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1245\/s10434-019-07597-0","volume":"26","author":"FO Imeokparia","year":"2019","unstructured":"Imeokparia FO, Hughes TM, Dossett LA, Jeruss JS, Chang AE, Sabel MS (2019) Axillary pathologic complete response in inflammatory breast cancer patients: implications for SLNB? Ann Surg Oncol 26(10):3374\u20133379","journal-title":"Ann Surg Oncol"},{"issue":"9712","key":"5529_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377\u2013384","journal-title":"Lancet"},{"key":"5529_CR16","unstructured":"The National Cancer Data Base. The American College of Surgeons. www.ncdb.org."},{"key":"5529_CR17","unstructured":"\"Surgical Axillary Stagng.\" NCCN Guideline Version 2.2019. https:\/\/www.nccn.org\/. Accessed 1 Jul 2019."},{"issue":"18","key":"5529_CR18","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2008.19.5750","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 27(18):2946\u20132953","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol."},{"key":"5529_CR19","doi-asserted-by":"crossref","unstructured":"Rosenberger LH, Ren Y, Thomas SM, et al. Axillary lymph node dissection in node-positive breast cancer: are 10-nodes adequate and when is enough, enough? Breast Cancer Res Treat 2019 Nov 18 [Epub ahead of print].","DOI":"10.1007\/s10549-019-05500-9"},{"issue":"3","key":"5529_CR20","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","volume":"7","author":"S Hidar","year":"2009","unstructured":"Hidar S, Bibi M, Gharbi O et al (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg (London, England). 7(3):272\u2013275","journal-title":"Int J Surg (London, England)."},{"issue":"3","key":"5529_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF02573060","volume":"9","author":"V Stearns","year":"2002","unstructured":"Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235\u2013242","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"5529_CR22","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","volume":"18","author":"SM DeSnyder","year":"2018","unstructured":"DeSnyder SM, Mittendorf EA, Le-Petross C et al (2018) Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 18(1):e73\u2013e77","journal-title":"Clin Breast Cancer."},{"issue":"3","key":"5529_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.amjsurg.2011.10.016","volume":"204","author":"H Caretta-Weyer","year":"2012","unstructured":"Caretta-Weyer H, Sisney GA, Beckman C et al (2012) Impact of axillary ultrasound and core needle biopsy on the utility of intraoperative frozen section analysis and treatment decision making in women with invasive breast cancer. Am J Surg. 204(3):308\u2013314","journal-title":"Am J Surg."},{"issue":"1","key":"5529_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.breast.2008.09.003","volume":"18","author":"PD Britton","year":"2009","unstructured":"Britton PD, Provenzano E, Barter S et al (2009) Ultrasound guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? Breast 18(1):13\u201316","journal-title":"Breast"},{"issue":"10","key":"5529_CR25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol: Off J Am Soc Clin Oncol. 34(10):1072\u20131078","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol."},{"issue":"4","key":"5529_CR26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","volume":"263","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0\u2013T4, N1\u2013N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance). Ann Surg 263(4):802\u2013807","journal-title":"Ann Surg"},{"issue":"4","key":"5529_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM et al (2018) The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg 268(4):591\u2013601","journal-title":"Ann Surg"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-05529-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05529-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T19:17:20Z","timestamp":1610997440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-05529-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5529"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05529-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,20]]},"assertion":[{"value":"29 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Force is a consultant for Genomic Health, Nanostring, and Pfizer, Dr. King is a consultant for Genomic Health, Dr. Hyslop is a consultant for AbbVie, and Dr. Fayanju, Mr. Ren, Dr. Greenup, Dr. Plichta, Dr. Rosenberger, Dr. Suneja, Dr. Devi, Dr. Nakhlis, and Dr. Hwang have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with human participants or animals performed by any of the authors as de-identified data were used and the study was granted exempt status by our institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}